<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190925044884N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-12-24</date_registration>
      <primary_sponsor>Kermanshah University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the Effect of Transcutaneous Electrical Acupoint Stimulation and Infrared on the Severity of the restless leg Syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Effect of Transcutaneous Electrical Acupoint Stimulation and Infrared on the Severity of the restless leg Syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/42556</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Factorial, Purpose: Treatment, Randomization description: In this study, a simple randomization method will be used. The random number table will be used to select the samples and place them in the intervention and control modes, Blinding description: Participants in this study will not know which of the intervention and control groups they belong to. The data analyzer also does not know which data belongs to which group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Restless leg syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Transcutaneous Electrical Acupoint Stimulation.In the electrical stimulation intervention group, skin stimulation was performed with AcuHealth (Australian Made) at specified locations.Electrical stimulation of the specimens was performed for each sample for 4 consecutive weeks, 3 times a week, and every 5 minutes. Intervention 2: Intervention group: Infrared.In the infrared intervention group, infrared light therapy sessions are conducted in two sessions, with each individual in the intervention group being treated three times a week for one month. The BioBeam940 (Israel-made) portable, FDA-approved, portable, hand-held device is used to conduct infrared light therapy sessions. In this regard, the 2 nm wavelength in the NIR range, with a power of 1 mW / cm2, a frequency of 2 Hz, a maximum focusing power of 2 mW, and a 2 degree radiation angle are applied to each acupuncture point of each foot as well as the entire plantar surface of each. The foot will be exposed to infrared light It should be noted that the energy transfer to each acupuncture point is two minutes in order to transmit energy to the foot from the method used in the bath so that the infrared probe in The whole plantar surface will move about for 5 minutes, so each person will have to walk 5 minutes in total. Session receives infrared light. Intervention 3: Control group: Intervention group: Transcutaneous Electrical Acupoint Stimulation.While the sessions in the control group will be administered in the form of dummy treatment, the researcher only pretends that he is undergoing electrical stimulation therapy in the control group, but in fact, the acupuncture points of these individuals are not stimulated.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is After obtaining permission from the samples will be decided.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Nazarian Pirdosti</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Farabi Hospital, Dollat Abad, Kermanshah, Iran</address>
        <city>kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6715847141</zip>
        <telephone>+98 83 4512 6851</telephone>
        <email>mnazarianpirdosti@gmail.com</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Behnam Khaledi Paveh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Farabi Hospital, Dollat Abad, Kermanshah, Iran</address>
        <city>kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6715847141</zip>
        <telephone>+98 83 3816 2401</telephone>
        <email>bkhaledipaveh@kums.ac.ir</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Informed consent to participate in the study
Having restless legs syndrome
Age range between 18 and 65 years
Not being cancer
Not receiving pharmacological and non-pharmacological treatment to relieve restless leg syndrome
Not having pacemaker</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Failure to attend more than 3 sessions
Using Restless Foot Syndrome Soothing Medications
Migration
Death</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G25.81</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Restless legs syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Transcutaneous Electrical Acupoint Stimulation.In the electrical stimulation intervention group, skin stimulation was performed with AcuHealth (Australian Made) at specified locations.Electrical stimulation of the specimens was performed for each sample for 4 consecutive weeks, 3 times a week, and every 5 minutes.</i_keyword>
      <i_keyword>Intervention group: Infrared.In the infrared intervention group, infrared light therapy sessions are conducted in two sessions, with each individual in the intervention group being treated three times a week for one month. The BioBeam940 (Israel-made) portable, FDA-approved, portable, hand-held device is used to conduct infrared light therapy sessions. In this regard, the 2 nm wavelength in the NIR range, with a power of 1 mW / cm2, a frequency of 2 Hz, a maximum focusing power of 2 mW, and a 2 degree radiation angle are applied to each acupuncture point of each foot as well as the entire plantar surface of each. The foot will be exposed to infrared light It should be noted that the energy transfer to each acupuncture point is two minutes in order to transmit energy to the foot from the method used in the bath so that the infrared probe in The whole plantar surface will move about for 5 minutes, so each person will have to walk 5 minutes in total. Session receives infrared light.</i_keyword>
      <i_keyword>Control group: Intervention group: Transcutaneous Electrical Acupoint Stimulation.While the sessions in the control group will be administered in the form of dummy treatment, the researcher only pretends that he is undergoing electrical stimulation therapy in the control group, but in fact, the acupuncture points of these individuals are not stimulated.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>In this study, we compared the effect of acupuncture points and infrared light on the severity of restless legs syndrome using the restless legs syndrome universal questionnaire whose score is below 4. Timepoint: In this study, we compared the efficacy of acupuncture points and infrared light on the severity of restless leg syndrome, the first measurement with a pre-test and the second with a post-test, and the third measurement to determine whether the method was effective. Whether or not treatment will continue, one month after the end of treatment, re-treatment will be perform. Method of measurement: Restless Foot Syndrome World Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kermanshah University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-09-17</approval_date>
        <contact_name>Ethics committee of Kermanshah University of Medical Sciences</contact_name>
        <contact_address>Branch of researchs and industry,Kermanshah University Of Medical Sciences, Shahid Beheshti Blvd, Kermanshah, Iran Kermanshah Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
